Medical Science Liaison / Senior Medical Science Liaison
Kura Oncology
Medical Science Liaison / Senior Medical Science Liaison
Kura Oncology
Develops precision oncology small-molecule therapeutics
Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
The base range for an MSL is $218,000 - $247,000 and a Senior MSL is $243,000 - $278,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
#LI-RM1
Kura’s Values that are used for candidate selection and performance assessments:
The Kura Package
Kura Oncology is a commercial-stage biopharmaceutical company committed to discovering and developing innovative precision medicines to help patients with cancer lead better, longer lives.
Through our deep understanding of cancer biology and decades of experience in precision oncology, we are studying the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, with the goal of improving long-term clinical benefit.
Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
If you are a California resident, please see the attached Privacy Notice CA Privacy Notice
Develops precision oncology small-molecule therapeutics
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. Its portfolio centers on small molecule drugs that target cancer cells with specific genetic mutations. The lead candidate, ziftomenib, inhibits the menin-KMT2A/MLL interaction to treat genetically defined acute myeloid leukemia (AML). Another program, tipifarnib, targets solid tumors such as head and neck squamous cell carcinoma (HNSCC) by blocking farnesyltransferase, a key enzyme in cancer signaling. Kura stresses collaboration with academic groups and other biopharma companies to advance its pipeline, with the goal of bringing targeted cancer therapies to patients in need. Unlike broader, non-specific approaches, Kura focuses on therapies matched to genetic alterations in tumors and on advancing a focused, clinically driven portfolio toward approval and commercialization in the global oncology market.
Explore more opportunities at Kura Oncology